|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/01/15 Biolase, Inc 10-Q 3/31/15 69:7.4M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 423K
2: EX-10.1 Material Contract HTML 67K
3: EX-10.3 Material Contract HTML 55K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
47: R1 Document and Entity Information HTML 42K
37: R2 Consolidated Balance Sheets (Unaudited) HTML 129K
45: R3 Consolidated Balance Sheets (Unaudited) HTML 49K
(Parenthetical)
49: R4 Consolidated Statements Of Operations And HTML 102K
Comprehensive Loss (Unaudited)
64: R5 Consolidated Statements Of Cash Flows (Unaudited) HTML 141K
39: R6 Description of Business and Basis of Presentation HTML 31K
44: R7 Summary of Significant Accounting Policies HTML 34K
34: R8 Stock-Based Awards and Per Share Information HTML 187K
26: R9 Inventory HTML 41K
65: R10 Property, Plant, and Equipment HTML 60K
51: R11 Intangible Assets and Goodwill HTML 112K
50: R12 Accrued Liabilities and Deferred Revenue HTML 95K
55: R13 Lines Of Credit and Other Borrowings HTML 35K
56: R14 Commitments and Contingencies HTML 48K
54: R15 Segment Information HTML 46K
57: R16 Concentrations HTML 50K
46: R17 Income Taxes HTML 29K
48: R18 Subsequent Event HTML 24K
53: R19 Accounting Policies (Policies) HTML 64K
69: R20 Stock-Based Awards and Per Share Information HTML 190K
(Tables)
60: R21 Inventory (Tables) HTML 39K
41: R22 Property, Plant, and Equipment (Tables) HTML 58K
52: R23 Intangible Assets and Goodwill (Tables) HTML 106K
43: R24 Accrued Liabilities and Deferred Revenue (Tables) HTML 98K
20: R25 Segment Information (Tables) HTML 39K
61: R26 Concentrations (Tables) HTML 48K
66: R27 Description of Business and Basis of Presentation HTML 32K
- Additional Information (Detail)
30: R28 Summary of Significant Accounting Policies - HTML 24K
Additional Information (Detail)
29: R29 Stock-Based Awards and Per Share Information - HTML 142K
Additional Information (Detail)
32: R30 Classification of Compensation Expense Associated HTML 37K
with Share-Based Payments (Detail)
33: R31 Assumptions Used in Estimating Fair Value of Stock HTML 30K
Options Granted (Detail)
35: R32 Summary of Option Activity (Detail) HTML 79K
18: R33 Cash Proceeds Along with Fair Value Disclosures HTML 37K
Related to Grants, Exercises, and Vested Options
(Detail)
58: R34 Summary of Warrant Activity (Detail) HTML 39K
40: R35 Components of Inventory (Detail) HTML 33K
42: R36 Inventory - Additional Information (Detail) HTML 24K
23: R37 Summary of Property, Plant, and Equipment (Detail) HTML 53K
68: R38 Property, Plant, and Equipment - Additional HTML 26K
Information (Detail)
14: R39 Intangible Assets and Goodwill - Additional HTML 26K
Information (Detail)
36: R40 Intangible Assets and Related Accumulated HTML 57K
Amortization (Detail)
63: R41 Components of Accrued Liabilities (Detail) HTML 51K
22: R42 Changes in Initial Product Warranty Accrual and HTML 39K
Expenses Under Initial and Extended Warranties
(Detail)
28: R43 Accrued Liabilities and Deferred Revenue - HTML 25K
Additional Information (Detail)
31: R44 Summary of Deferred Revenue (Detail) HTML 29K
38: R45 Lines of Credit and Other Borrowings - Additional HTML 87K
Information (Detail)
17: R46 Commitments and Contingencies - Additional HTML 111K
Information (Detail)
25: R47 Segment Information - Additional Information HTML 41K
(Detail)
15: R48 Summary of Net Revenue by Geographic Location HTML 28K
(Detail)
62: R49 Concentrations - Summary of Net Revenue from HTML 41K
Various Products (Detail)
21: R50 Concentrations - Additional Information (Detail) HTML 33K
59: R51 Income Taxes - Additional Information (Detail) HTML 34K
24: R52 Subsequent Event - Additional Information (Detail) HTML 38K
67: XML IDEA XML File -- Filing Summary XML 101K
16: EXCEL IDEA Workbook of Financial Reports XLSX 116K
27: EXCEL IDEA Workbook of Financial Reports (.xls) XLS 1.10M
8: EX-101.INS XBRL Instance -- biol-20150331 XML 1.39M
10: EX-101.CAL XBRL Calculations -- biol-20150331_cal XML 140K
11: EX-101.DEF XBRL Definitions -- biol-20150331_def XML 333K
12: EX-101.LAB XBRL Labels -- biol-20150331_lab XML 975K
13: EX-101.PRE XBRL Presentations -- biol-20150331_pre XML 695K
9: EX-101.SCH XBRL Schema -- biol-20150331 XSD 147K
19: ZIP XBRL Zipped Folder -- 0001564590-15-003181-xbrl Zip 114K
Exhibit 31.1
CERTIFICATION
I, Jeffrey M. Nugent, certify that:
|
1. |
I have reviewed this quarterly report on Form 10-Q for the period ended March 31, 2015 of BIOLASE, Inc.; |
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b. |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c. |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
d. |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a. |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
b. |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
|
Date: May 1, 2015 |
By: |
|
|
|
|
|
|
|
|
President and Chief Executive Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/1/15 | None on these Dates | ||
| For Period end: | 3/31/15 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/21 Biolase, Inc. 10-K 12/31/20 88:15M ActiveDisclosure/FA 12/08/20 Biolase, Inc. S-1/A 3:585K Donnelley … Solutions/FA |